Melissa Lynne Johnson

49PUBLICATIONS
426CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersPharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Jul 27, 2026
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.

|Apr 28, 2026
The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with KRAS Mutation-Positive Solid Tumors.

|Apr 22, 2026
Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices.

|Apr 03, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.

Melissa L Johnson, Giulia Fabbri, Carmela Ciardullo

|Mar 31, 2026
Reply to: Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS.

Melissa L Johnson

|Jan 09, 2026
MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario.

Jordi Rodon, Melissa L Johnson, Ben George

Pageof 9

Frequent Collaborators

8 joint publications

Byoung Chul Cho

8 joint publications

Enriqueta Felip

8 joint publications

Pasi A Jänne

6 joint publications

Namrata S Patil